Safety and Effectiveness of Microfocused Ultrasound for Treating Erythematotelangiectatic Rosacea
Schlessinger, J.; Lupin, M.; McDaniel, D.; George, R.
Journal of Drugs in Dermatology Jdd 18(6): 522
2019
ISSN/ISBN: 1545-9616 PMID: 31251544 Document Number: 17903
Background: Anecdotal reports indicate the use of microfocused ultrasound with visualization (MFU-V) improves facial redness.
Document emailed within 1 workday
Related Documents
Maas, C.S..; Joseph, J.H.. 2019: Safety and Effectiveness of Microfocused Ultrasound With Visualization for the Correction of Moderate to Severe Atrophic Acne Scars Journal of Drugs in Dermatology: Jdd 18(11): 1109-1114Casabona, G. 2018: Combined use of microfocused ultrasound and a calcium hydroxylapatite dermal filler for treating atrophic acne scars: A pilot study Journal of Cosmetic and Laser Therapy 20(5): 301-306
Hofmann, M.A.; Kokolakis, G. 2017: A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea Journal of Cosmetic and Laser Therapy 19(4): 222-224
Alexis, A.F.; Webster, G.; Preston, N.J.; Caveney, S.W.; Gottschalk, R.W. 2012: Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with rosacea: an analysis by Fitzpatrick skin type Journal of drugs in dermatology: JDD 11(10): 1219-1222
Urban, J.; Siripunvarapon, A.H.; Meekings, A.; Kalowitz, A.; Markowitz, O. 2014: Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment Journal of Drugs in Dermatology: Jdd 13(7): 821-826
Casabona, G.; Kaye, K. 2019: Facial Skin Tightening With Microfocused Ultrasound and Dermal Fillers: Considerations for Patient Selection and Outcomes Journal of drugs in dermatology: JDD 18(11): 1075-1082
Del Rosso, J.Q.; Preston, N.J.; Caveney, S.W.; Gottschalk, R.W. 2012: Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender Journal of Drugs in Dermatology: Jdd 11(6): 703-707
Fabi, S.G..; Joseph, J.; Sevi, J.; Green, J.B..; Peterson, J.Deaver. 2019: Optimizing Patient Outcomes by Customizing Treatment With Microfocused Ultrasound With Visualization: Gold Standard Consensus Guidelines from an Expert Panel Journal of drugs in dermatology: JDD 18(5): 426-432
Murty, J.; Firth, S. 1996: Effect of CSM's warning about safety of third generation oral contraceptives. Contraceptive effectiveness may be being sacrificed for safety Bmj 313(7053): 363
Del Rosso, J.Q.; Baldwin, H.; Webster, G. 2008: American Acne & Rosacea Society rosacea medical management guidelines Journal of drugs in dermatology: JDD 7(6): 531-533
Elewski, B.E. 2009: Results of a national rosacea patient survey: common issues that concern rosacea sufferers Journal of Drugs in Dermatology: Jdd 8(2): 120-123
Schmidt, J.B.; Raff, M.; Spona, J. 1983: Do sexual steroids contribute to the pathomechanism of rosacea? A study of estrogen and androgen receptors in acne rosacea Acta Dermato-Venereologica 63(1): 64-66
Michel, J-L.; Cabibel, F. 2003: Frequency, severity and treatment of ocular rosacea during cutaneous rosacea Annales de Dermatologie et de Venereologie 130(1 Pt 1): 20-24
Wolf, J.E.; Kerrouche, N.; Arsonnaud, S. 2006: Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea Cutis 77(4 Suppl): 3-11
Chang, A.L.S.; Alora-Palli, M.; Lima, X.T.; Chang, T.C.; Cheng, C.; Chung, C.M.; Amir, O.; Kimball, A.B. 2012: A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks Journal of Drugs in Dermatology: Jdd 11(3): 333-339
Meynadier, J.; Guilhou, J.J. 1983: Papulopustular rosacea (traditional acne rosacea) La Revue du Praticien 33(35): 1837-1843
Baumann, L.; Goldberg, D.J.; Stein Gold, L.; Tanghetti, E.A.; Lain, E.; Kaufman, J.; Weng, E.; Berk, D.R.; Ahluwalia, G. 2018: Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated with Rosacea: Findings from the Second REVEAL Trial Journal of Drugs in Dermatology: Jdd 17(3): 290-298
Kircik, L.H.; DuBois, J.; Draelos, Z.D.; Werschler, P.; Grande, K.; Cook-Bolden, F.E.; Weng, E.; Berk, D.R.; Ahluwalia, G. 2018: Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated with Rosacea: Findings from the first REVEAL Trial Journal of Drugs in Dermatology: Jdd 17(1): 97-105
Moore, A.; Kempers, S.; Murakawa, G.; Weiss, J.; Tauscher, A.; Swinyer, L.; Liu, H.; Leoni, M. 2014: Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study Journal of Drugs in Dermatology: Jdd 13(1): 56-61
Fowler, J.; Jackson, M.; Moore, A.; Jarratt, M.; Jones, T.; Meadows, K.; Steinhoff, M.; Rudisill, D.; Leoni, M. 2013: Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies Journal of Drugs in Dermatology: Jdd 12(6): 650-656